Analysis Novo Nordisk: A New Indication Beckons Even as Patent Walls Crumble in Emerging Markets
A shift in medical classification could open a fresh avenue for Novo Nordisk’s GLP-1 franchise, even as the Danish drugmaker grapples with accelerating patent erosion in key emerging markets. On...